Immunotherapy targeting cancer fusion protein may hold key to treating rare liver cancer

Findings from scientists at St. Jude Children’s Research Hospital and The University of Tennessee Health Science Center suggest T-cell therapy could effectively treat fibrolamellar carcinoma.

Read more: https://www.stjude.org/media-resources/news-releases/2024-medicine-science-news/immunotherapy-targeting-cancer-fusion-protein-may-hold-key-to-treating-rare-liver-cancer.html